Pharmaceuticals, Biotechnology & Life Sciences

Amgen invests $300 M to expand its Puerto Rico biomanufacturing facility, boosting global supply, job creation and U.S. production resilience.

FTSE 100 slips into loss zone as Haleon, HSBC and InterContinental Hotels dip—investors eye market signals, healthcare pros monitor regulatory shifts.

Teva’s upcoming executive talk at BofA Health Care reveals its pivot to neuroscience, immunology and biopharma while insiders sell shares—insights on strategy and equity moves.

Zoetis’ 2025‑26 results show record revenue of $15.23 bn, a 8.4 % YoY jump, driven by global expansion, digital transformation, and higher‑margin specialty products.

FDA reviews reveal pharma’s push to expand drug indications to earlier‑line and underserved patients, driving market share, pricing, and reimbursement shifts.

Explore how Natera’s insider‑sale of RSUs signals strong cash flow and the company’s strategy to invest in next‑gen liquid‑biopsy tests, driving growth in the $26 bn genomic diagnostics market.

Agilent names Michael Buckner as new chief legal officer, boosting governance and IP protection as the company tackles evolving regulatory challenges and future M&A.

Pfizer’s next earnings report shows modest quarterly gains but a sharp FY uptick driven by new obesity and rare‑disease drugs, highlighting patent cliffs, market‑access tactics, and M&A opportunities.

Discover how Novo Nordisk’s stock gains, GLP‑1 drug benefits and new eye‑risk lawsuits shape investor sentiment and future growth prospects.

Argenx SE’s share price jumped 12 % in the last year thanks to a strong antibody pipeline, growing revenue and better margins, but regulatory delays, clinical risk, and competition may temper this rally.